Pharma Journalist -

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model,…
Read More...

GSK plc announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the…
Read More...

The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, announced a strategic collaboration to design and…
Read More...

Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug (IND)-enabling chemistry,…
Read More...

GSK plc announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Benlysta (belimumab), a B-cell inhibiting monoclonal antibody, for the…
Read More...

Cybin Inc., a biopharmaceutical company focused on progressing Psychedelics to Therapeutics is pleased to announce that it has received approval from an independent ethics committee in…
Read More...

Daewoong Pharmaceutical(CEO Seng-ho Jeon and Chang-jae Lee) has secured an exclusive licensing agreement with CS Pharmaceuticals ("CSP"), a UK based multinational company focused on the…
Read More...

uniQure N.V. and Apic Bio announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a…
Read More...

Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration ("FDA") has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV)…
Read More...

Sun Pharmaceutical announced that it has acquired three brands viz. Disperzyme (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD (Trypsin BP 48 mg,…
Read More...